|Trade names||Easyef, Genesoft, Kang He Su, Regen-D|
|Synonyms||Recombinant human epidermal growth factor; rhEGF; DWP-401|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||6222.026 g/mol g·mol−1|
|3D model (JSmol)|
Nepidermin (brand name Easyef), also known as recombinant human epidermal growth factor (rhEGF), is a recombinant form of human epidermal growth factor (EGF) and a cicatrizant (a drug that promotes wound healing through formation of scar tissue). It was developed by Daewoong Pharmaceutical. As a recombinant form of EGF, nepidermin is an agonist of the epidermal growth factor receptor (EGFR), and is the first EGFR agonist to be marketed.
As of 2017 it was in clinical trials in South Korea for the treatment of stomatitis (inflammation of the mouth or lips) and for reversal of skin side effects caused by erlotinib (an EGFR inhibitor).
- "Nepidermin". Drugs.com. Retrieved 3 June 2017.
- "Nepidermin". AdisInsight. Retrieved 3 June 2017.
- Lau, Hui-Chong; Kim, Aeri (2016). "Pharmaceutical perspectives of impaired wound healing in diabetic foot ulcer". Journal of Pharmaceutical Investigation. 46 (5): 403–423. doi:10.1007/s40005-016-0268-6. ISSN 2093-5552.
- Yuan A, Sonis S (2014). "Emerging therapies for the prevention and treatment of oral mucositis". Expert Opin Emerg Drugs. 19 (3): 343–51. doi:10.1517/14728214.2014.946403. PMID 25102771.
|This protein-related article is a stub. You can help Wikipedia by expanding it.|
|This dermatologic drug article is a stub. You can help Wikipedia by expanding it.|